131.80

0.02% 0.20

Neurocrine Biosciences Inc (NBIX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Neurocrine Biosciences Inc stock is traded at $131.80, with a volume of 786.48K. It is up +0.02% in the last 24 hours and up +2.72% over the past month. Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Previous Close:

$131.60

Open:

$130.93

24h Volume:

786.48K

Relative Volume:

0.70

Market Cap:

$13.21B

Revenue:

$2.86B

Net Income/Loss:

$478.60M

P/E Ratio:

28.24

EPS:

4.6676

Net Cash Flow:

$748.70M

1W Performance:

+2.25%

1M Performance:

+2.72%

6M Performance:

-5.60%

1Y Performance:

+37.61%

1-Day Range:

$125.31

$132.68

1-Week Range:

$125.31

$133.99

52-Week Range:

$84.23

$160.18

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name

Neurocrine Biosciences Inc

Sector

Healthcare (1117)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

(858) 617-7600

Address

6027 EDGEWOOD BEND COURT, SAN DIEGO, CA

Employee

2,000

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

NBIX's Discussions on Twitter

Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NBIX Neurocrine Biosciences Inc	131.62	13.21B	2.86B	478.60M	748.70M	4.6676
TAK Takeda Pharmaceutical Co Adr	18.30	59.20B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	117.97	49.79B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.95	44.27B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	29.56	35.03B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	557.86	24.75B	3.18B	1.33B	1.04B	27.90

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Wolfe Research	Outperform
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-21-25	Initiated	Citigroup	Buy
Jul-21-25	Initiated	Truist	Buy
Jul-10-25	Initiated	Goldman	Buy
Apr-15-25	Upgrade	Needham	Hold → Buy
Apr-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-11-25	Initiated	Deutsche Bank	Hold
Oct-10-24	Resumed	Raymond James	Outperform
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-13-23	Resumed	Citigroup	Neutral
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Aug-21-23	Reiterated	Mizuho	Neutral
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform
May-04-23	Upgrade	Guggenheim	Neutral → Buy
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-14-22	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-22	Initiated	UBS	Buy
Sep-26-22	Initiated	Wells Fargo	Equal Weight
Jun-06-22	Resumed	Jefferies	Buy
Mar-03-22	Downgrade	Piper Sandler	Overweight → Neutral
Feb-25-22	Upgrade	Goldman	Neutral → Buy
Jan-18-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-19-21	Initiated	BMO Capital Markets	Underperform
Nov-17-21	Upgrade	JP Morgan	Neutral → Overweight
Oct-14-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-23-21	Resumed	Needham	Hold
Aug-06-21	Downgrade	Canaccord Genuity	Buy → Hold
May-18-21	Resumed	Goldman	Neutral
May-06-21	Upgrade	Barclays	Equal Weight → Overweight
Feb-02-21	Initiated	Raymond James	Outperform
Sep-30-20	Initiated	The Benchmark Company	Hold
Aug-04-20	Downgrade	JP Morgan	Overweight → Neutral
Jun-29-20	Downgrade	Goldman	Buy → Neutral
Jun-09-20	Initiated	Wedbush	Outperform
Mar-06-20	Initiated	Citigroup	Buy
Feb-27-20	Initiated	Barclays	Equal Weight
Feb-24-20	Initiated	William Blair	Outperform
Feb-06-20	Initiated	Mizuho	Neutral
Feb-05-20	Reiterated	H.C. Wainwright	Buy
Dec-13-19	Downgrade	Credit Suisse	Outperform → Neutral
Aug-07-19	Initiated	RBC Capital Mkts	Outperform
Jul-16-19	Initiated	Oppenheimer	Outperform
Jun-05-19	Initiated	Guggenheim	Neutral
May-21-19	Initiated	Credit Suisse	Outperform
Apr-22-19	Upgrade	JP Morgan	Neutral → Overweight
Apr-12-19	Initiated	Evercore ISI	Outperform
Feb-06-19	Reiterated	BofA/Merrill	Buy
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Dec-13-18	Initiated	Goldman	Buy
Nov-21-18	Initiated	Canaccord Genuity	Buy

View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

09:53 AM

Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - Reuters

09:53 AM

09:35 AM

Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal - Yahoo Finance

09:35 AM

09:12 AM

Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal - marketscreener.com

09:12 AM

09:03 AM

Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics for $2.9B - Contract Pharma

09:03 AM

08:13 AM

Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market - Benzinga

08:13 AM

08:01 AM

Neurocrine to Acquire Soleno, Expanding Rare Disease Portfolio - TipRanks

08:01 AM

07:54 AM

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash - marketscreener.com

07:54 AM

07:53 AM

Soleno to Be Acquired by Neurocrine in $53-Per-Share Tender Offer - TradingView

07:53 AM

07:50 AM

Neurocrine Biosciences (NBIX) agrees to buy Soleno (SLNO) for $53/share - Stock Titan

07:50 AM

07:46 AM

Neurocrine to buy Soleno (NASDAQ: SLNO) in $2.9B all-cash deal - Stock Titan

07:46 AM

07:42 AM

Neurocrine to Buy Soleno Therapeutics for $2.9 Billion - Bloomberg.com

07:42 AM

07:40 AM

Neurocrine Biosciences Inc if deal terminated under some circumstances Soleno will pay co termination fee of $95.3 million - marketscreener.com

07:40 AM

07:39 AM

Neurocrine Biosciences Inc If Deal Terminated Under Some Circumstances Soleno Will Pay Co Termination Fee Of $95.3 Million - TradingView

07:39 AM

07:35 AM

Neurocrine (NBIX) to acquire Soleno in $2.9B rare-disease portfolio deal - Stock Titan

07:35 AM

07:34 AM

Neurocrine Biosciences : Presentation (FINAL NBIX SLNO Investor Presentation 0466 Final) - marketscreener.com

07:34 AM

07:24 AM

This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal. - Barron's

07:24 AM

07:13 AM

Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move. - MarketWatch

07:04 AM

07:00 AM

Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PR Newswire

07:00 AM

05:56 AM

Soleno Therapeutics (SLNO) Stock Jumps 30% on Neurocrine $2.5B Buyout Report - CoinCentral

05:56 AM

Apr 05, 2026

Neurocrine nears $2.5B-plus deal to buy Soleno TherapeuticsFT (NBIX:NASDAQ) - Seeking Alpha

Apr 05, 2026

Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment - ft.com

Apr 05, 2026

Neurocrine bets nearly $3bn on deal for insatiable hunger treatment - ft.com

Apr 05, 2026

Nisa Investment Advisors Reduces Neurocrine Biosciences Stake - National Today

Apr 05, 2026

Nisa Investment Advisors LLC Sells 21,945 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Apr 05, 2026

Risks Report: Is Neurocrine Biosciences Inc a turnaround storyMarket Weekly Review & High Win Rate Trade Tips - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Q4 2025 earnings call transcript - msn.com

Apr 04, 2026

A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Data In Older Tardive Dyskinesia Patients - Sahm

Apr 04, 2026

Should You be Optimistic on Neurocrine Biosciences (NBIX)? - msn.com

Apr 04, 2026

Apr 03, 2026

Neurocrine Biosciences Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Apr 03, 2026

NBIX Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai

Apr 03, 2026

Apr 02, 2026

8,437 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Nilsine Partners LLC - MarketBeat

Apr 02, 2026